A Phase 3, Randomized, Multi-Center, Multi-National, Open-Label, Active Comparator Study to Evaluate the Efficacy and Safety of Genz-112638 in Patients With Gaucher Disease Type 1 Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)

Trial Profile

A Phase 3, Randomized, Multi-Center, Multi-National, Open-Label, Active Comparator Study to Evaluate the Efficacy and Safety of Genz-112638 in Patients With Gaucher Disease Type 1 Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Feb 2017

At a glance

  • Drugs Eliglustat (Primary) ; Imiglucerase
  • Indications Gaucher's disease type I
  • Focus Therapeutic Use
  • Acronyms ENCORE
  • Sponsors Genzyme Corporation
  • Most Recent Events

    • 06 Feb 2017 Results (n=46) assessing long-term (4 years) safety and efficacy of eliglustat, published in the Blood.
    • 08 Dec 2015 Results of this and two other trials (see profile 239253 and 239258) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 13 Jun 2015 Results published in the Lancet.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top